Special Issue

Cystic Fibrosis and Personalized Medicine

Message from the Guest Editors

Cystic fibrosis is the most prevalent monogenetic disease worldwide. Over 2000 different defects in the cystic fibrosis transmembrane conductance regulator (CFTR) gene have been described, not only leading to a highly diverse phenotype of the disease, but also to the development of a plethora of gene-defect specific therapies. Many new techniques and models have been developed to unravel the genotype-phenotype relationship and to develop and apply new molecules which can modify CFTR-protein function. In addition to clinical and radiological evaluation, functional measurements such as sweat testing, intestinal current measurements, and patient-derived cell models from airway and gut tissue have become available. Today, these tools are more and more helpful in driving treatment of cystic fibrosis into theratyping and real personalized medicine. For this Special Issue, we invite review articles and original studies addressing the latest developments in patient-specific drug development and evaluation of effects in patients with cystic fibrosis.

Guest Editors

Prof. Dr. Cornelis K. van der Ent

Department of Pulmonology Patient Care, Utrecht University Medical Center, Utrecht, The Netherlands

Prof. Dr. Harry G. M. Heijerman

Department of Pulmonology, University Medical Center Utrecht, Utrecht. The Netherlands

Deadline for manuscript submissions

closed (25 November 2021)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/58483

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

